JPMorgan Reinstates BeOne Medicines (ONC) at Overweight
Tweet
Share
E-mailGet Alerts ONC Hot Sheet
Price: $297.65 +2.38%
Rating Summary:
6 Buy, 1 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 2
Rating Summary:
6 Buy, 1 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 2
Join SI Premium – FREE
JPMorgan analyst Jessica Fye reinstates coverage on BeOne Medicines (NASDAQ: ONC) with a Overweight rating and a price target of $415.00.
For an analyst ratings summary and ratings history on BeOne Medicines click here. For more ratings news on BeOne Medicines click here.
Shares of BeOne Medicines closed at $297.01 yesterday.
You May Also Be Interested In
- BeOne Medicines (ONC) Reiterated at Market Outperform by Citizens on Phase 3 Results
- BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma
- JPMorgan Assumes Kanzhun Ltd. (BZ) at Overweight
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
